# Eli Lilly Q2 2026 Revenue Surge

> Lilly's Mounjaro revenue nearly doubled to $9.94 billion in Q2 2026, driving 48% revenue growth.
- Title: Eli Lilly Q2 2026 Revenue Surge | Shortify
- Summary: Lilly's Mounjaro revenue nearly doubled to $9.94 billion in Q2 2026, driving 48% revenue growth. Eli Lilly reported $23 billion in Q2 2026 revenue, with…
- Keywords: mounjaro, eli lilly, q2 2026, revenue, cardiometabolic, geographic pricing, market share, lilly, tirzepatide, zepbound, foundayo, retatrutide
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/eli-lilly-q2-2026-mounjaro-revenue-surge-geographic-pricing-dynamics-and-market-share-leadership
- Author: Newsdesk
- Published: 2026-10-01T20:15:35+00:00
- Read time: 1 min
- Topics: mounjaro, eli lilly, q2 2026, revenue, cardiometabolic, geographic pricing, market share, lilly, tirzepatide, zepbound, foundayo, retatrutide
## Q2 2026 Results
Eli Lilly reported non-GAAP earnings per share of $8.38, exceeding consensus estimates of $6.58.
## Mounjaro Revenue Surge
Mounjaro revenue nearly doubled to $9.94 billion in Q2 2026, a 91% year-over-year increase.
## Market Share Leadership
Mounjaro now constitutes approximately 43% of total quarterly revenue, cementing its role as the growth engine.
## Zepbound and Foundayo Impact
Zepbound contributed to revenue acceleration, while Foundayo, Lilly's April 2026 oral obesity pill, marked its first full reporting period.
## Full-Year Guidance Raising
Lilly raised full-year 2026 revenue guidance to $85.0 billion to $87.0 billion, up from $82.0 billion to $85.0 billion.
## Geographic Pricing Shift
International Mounjaro sales jumped 172% year-over-year to $5.14 billion, while U.S. sales reached $4.8 billion.
## Pricing and Margin Dynamics
International Mounjaro sales saw a 36% price decline amid volume growth, reflecting competitive pressure and healthcare cost containment.
## Key takeaway

Eli Lilly reported $23 billion in Q2 2026 revenue, with Mounjaro contributing $9.94 billion, a 91% year-over-year increase.